Search PubMed⌕ Search

Biomedical subjects

K Karrer

Publications and source records attributed to K Karrer.

At least 55 records · Page 3Linked to original sources
PubMed1977

[Therapy of solid tumors using high-dose methotrexate and citrovorum factor].

Methotrexat (250-1100 mg/m2) was administered to 38 patients with malignant tumors by infusion of either 6 hours or of 75 minutes duration. MTX-infusion and continued at 3-6 hours interval for Citrovorum factor rescue was started 2 hours after 24 to 72 hours. 7 different MTX doses and rescue schedules were tested. It could be shown that MTX in the dose range used is effective in various tumors when CF-rescue is not higher than 7% of the administered MTX-dose, only occasionally therapeutic success was observed with higher doses. In the group of patients where CF-rescue was lower than 7% of the MTX dose on 9/14 patients objective tumor-regressions could be achieved. Conclusions drawn are discussed and the necessity of further investigations is emphasized.

Administration, Oral↗
PubMed1976

[ Intermittent, longterm polychemotherapy in combination with radical operation of bronchial carcinoma (author's transl)].

A preliminary evaluation of a randomized, prospective clinical study of combined polychemotherapy in bronchial carcinoma is presented. The comparison of survival-curves shows a positive tendency in favor of the treatment and justifies the continuation and extension of the study. The data presented are based on the findings of 106 patients who underwent radical surgical operations due to bronchial carcinoma and of 114 patients as a comparison who in addition received aftertreatment with high doses of cytostatics applied intermittently. The importance of the influence of the clinical symptoms on the prognosis and on the effect of the Chemotherapy is emphasized.

Adult↗
PubMed1975

[The combined treatment of bronchial carcinoma (author's transl)].

A preliminary assessment of a chemotherapeutic study is presented. The polychemotherapy was given as a high dosage intermittent stosstherapy with 3 infusions at intervals of a week for 3 years. The group of randomized controls included 126 patients who were classified according to the stage classification of the TNM system and Feinstein's system, which takes into account the clinical symptoms. Comparison of the death rates with the controls shows a distinct advantage in favor of the patients treated chemotherapeutically in all TNM classes.

Adenocarcinoma↗
PubMed1975

[Smoking habits and epidemiology of lung cancer in Austria. III. Changes in lung cancer mortality in men].

It has been possible to show that the international trend of a reduced mortality rate in lung cancer of men can also be demonstrated in the Austrian population. By means of cohort-analysis this trend has been attributed mainly to a reduced mortality in younger male population. The improvement in the quality of cigarettes, namely the reduction in the amount of carcinogens and its relation to the reduction of lung cancer death rates will be discussed. At the present time, it is impossible to decide whether or not this reduced mortality rate will remain constant in the future or whether these results may be interpreted as expressing an increased period of latency in pulmonary carcinoma.

Austria↗
PubMed1975

[Chemotherapy of bronchial carcinomas (author's transl)].

Since the autumn of 1969, studies of surgical adjuvant chemotherapy and of chemotherapy and of chemotherapy alone in bronchogenic carcinoma have been undertaken in a cooperative trial group. Preliminary data from 171 radically operated patients, 88 randomized control patients, and 460 inoperable patients receiving chemotherapy only are presented. Chemotherapy was carried out as follows: 1-2 weeks after surgery the first intravenous infusion of 500 ml of 5% Leavulose including 12 mg/kg of cyclophosphamide, 12 mg/kg of 5-fluorouracil, 0.5 mg/kg of methotrexate, and 0,1 mg/kg of vinblastine was administered. The protocol requires the administration of 13 such infusions within 3 years after the operation. In general, the treatment which consisted of a total of 1445 infusions administered to 171 radically operated patients, was well tolerated and caused only minor side effects. The survival rate of the treated group of patients (calculated by the life-table method) appears promising compared with the survival rate of the randomized and historical control patients. The subdivision of patients into Feinstein categories shows a great variation, indicating the importance of the clinical parameters in influencing the prognosis. Based on a total of 2752 chemotherapeutic infusions in 460 patients with inoperable bronchogenic carcinoma, it can be stated that the treatment used was surprisingly well tolerated considering the advanced stage of disease and therefore the poorer general condition of these patients. These preliminary results justify the continuation of these clinical trials in a larger cooperative study group.

Antineoplastic Agents↗